SURMOUNT-OSA misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Trial design
Page 13 of 32 of this archive, newest first.
Why your laboratory interval differs from the one in the textbook
A flag is a probability statement about a population. It is not a statement about the person holding the printout.
From the floor in Wuhan: 12 posters, one theme
Reported from the sessions, and from the two hours afterwards.
LEADER misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
From the floor in Hong Kong: 5 posters, one theme
Reported from the sessions, and from the two hours afterwards.
SURMOUNT-2 was built to answer the stopping question, and it did
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
The dose that got you here and the dose that keeps you here
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
The three-times-upper-limit convention, and where it came from
What the renal and hepatic outcome programmes actually measured, and over what duration.
From the floor in Tianjin: 4 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What the protein literature actually shows, and in whom it was shown
Where the familiar figures come from, what populations they were measured in, and how far the extrapolation reaches.
From the floor in Shenzhen: 8 posters, one theme
Reported from the sessions, and from the two hours afterwards.
REWIND misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Sarcopenia is a diagnosis, not a synonym for losing lean mass
A tour of the source literatures, with an assessment of how far each legitimately reaches.
STEP 1 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Coming off: what the pharmacology permits
What a slow reduction could plausibly buy, and what it certainly cannot prevent.
SURPASS-2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
What the upper limit of normal for ALT should be, and why it is not
The reference interval for alanine aminotransferase in most laboratories is derived from a population that included people with undiagnosed fatty liver.
FLOW misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURPASS-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.